Cargando…
Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin
Enfortumab vedotin is an antibody-drug conjugate against nectin-4 that is recently being used in the management of patients with urothelial carcinoma. The common adverse events include rashes, peripheral neuropathy, and hyperglycemia. Only a few cases of associated respiratory symptoms have been rep...
Autores principales: | Homma, Takamasa, Tanaka, Kuniaki, Takeda, Naoya, Okada, Yu, Torii, Shota, Esaki, Hideki, Sakakibara, Takashi, Takimoto, Norio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601777/ https://www.ncbi.nlm.nih.gov/pubmed/37900848 http://dx.doi.org/10.1159/000534150 |
Ejemplares similares
-
Enfortumab Vedotin in urothelial cancer
por: Alt, Marie, et al.
Publicado: (2020) -
Drug extravasation with Enfortumab vedotin
por: Grant, Christopher Ryan, et al.
Publicado: (2023) -
Flexural Exanthema From Enfortumab Vedotin
por: Keerty, Dinesh, et al.
Publicado: (2020) -
Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
por: Hanna, Kirollos S.
Publicado: (2020) -
THU354 Enfortumab Vedotin Induced Refractory Hyperglycemia
por: Hussein, Marwah, et al.
Publicado: (2023)